Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Sandner

Showing results (11-20 of 109) with videos related to

Pageof 11
Sort By:
Current Urology Reports|September 4, 2008
Vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasiaHartmut Porst, Peter Sandner, Ernst Ulbrich
Naunyn-Schmiedeberg'S Archives of Pharmacology|October 12, 2017
Meeting report of the 8<sup>th</sup> International Conference on cGMP "cGMP: generators, effectors, and therapeutic implications" at Bamberg, Germany, from June 23 to 25, 2017Andreas Friebe, Peter Sandner, Achim Schmidtko
Gerontology|October 27, 2016
The Potential of sGC Modulators for the Treatment of Age-Related Fibrosis: A Mini-ReviewPeter Sandner, Peter Berger, Christoph Zenzmaier
Naunyn-Schmiedeberg'S Archives of Pharmacology|January 25, 2018
Correction to: Meeting report of the 8<sup>th</sup> International Conference on "cGMP BcGMP: generators, effectors, and therapeutic implications" at Bamberg, Germany, from June 23 to 25, 2017Andreas Friebe, Peter Sandner, Achim Schmidtko
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|April 17, 2008
Plasma concentrations of matrix metalloproteinase-2, tissue inhibitor of metalloproteinase-1 and osteopontin reflect severity of heart failure in DOCA-salt hypertensive ratFrank Kramer, Peter Sandner, Martina Klein, et al.
Biochemical Pharmacology|February 13, 2019
A novel soluble guanylyl cyclase activator, BR 11257, acts as a non-stabilising partial agonist of sGCChristin Elgert, Anne Rühle, Peter Sandner, et al.
Journal of Pharmaceutical and Biomedical Analysis|February 8, 2020
Thermal shift assay: Strengths and weaknesses of the method to investigate the ligand-induced thermostabilization of soluble guanylyl cyclaseChristin Elgert, Anne Rühle, Peter Sandner, et al.
BJU International|September 8, 2006
Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptomsHanna Tinel, Beatrix Stelte-Ludwig, Joachim Hütter, et al.
Handbook of Experimental Pharmacology|December 1, 2016
Novel sGC Stimulators and sGC Activators for the Treatment of Heart FailureStefanie Breitenstein, Lothar Roessig, Peter Sandner, et al.
Hypertension (Dallas, Tex. : 1979)|January 19, 2002
Inflammatory cytokines stimulate adrenomedullin expression through nitric oxide-dependent and -independent pathwaysKarl-Heinz Hofbauer, Ellen Schoof, Armin Kurtz, et al.
Pageof 11

Showing results (11-20 of 109) with videos related to

Sort By:
Pageof 11
Current Urology Reports|September 4, 2008
Vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasiaHartmut Porst, Peter Sandner, Ernst Ulbrich
Naunyn-Schmiedeberg'S Archives of Pharmacology|October 12, 2017
Meeting report of the 8<sup>th</sup> International Conference on cGMP "cGMP: generators, effectors, and therapeutic implications" at Bamberg, Germany, from June 23 to 25, 2017Andreas Friebe, Peter Sandner, Achim Schmidtko
Gerontology|October 27, 2016
The Potential of sGC Modulators for the Treatment of Age-Related Fibrosis: A Mini-ReviewPeter Sandner, Peter Berger, Christoph Zenzmaier
Naunyn-Schmiedeberg'S Archives of Pharmacology|January 25, 2018
Correction to: Meeting report of the 8<sup>th</sup> International Conference on "cGMP BcGMP: generators, effectors, and therapeutic implications" at Bamberg, Germany, from June 23 to 25, 2017Andreas Friebe, Peter Sandner, Achim Schmidtko
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|April 17, 2008
Plasma concentrations of matrix metalloproteinase-2, tissue inhibitor of metalloproteinase-1 and osteopontin reflect severity of heart failure in DOCA-salt hypertensive ratFrank Kramer, Peter Sandner, Martina Klein, et al.
Biochemical Pharmacology|February 13, 2019
A novel soluble guanylyl cyclase activator, BR 11257, acts as a non-stabilising partial agonist of sGCChristin Elgert, Anne Rühle, Peter Sandner, et al.
Journal of Pharmaceutical and Biomedical Analysis|February 8, 2020
Thermal shift assay: Strengths and weaknesses of the method to investigate the ligand-induced thermostabilization of soluble guanylyl cyclaseChristin Elgert, Anne Rühle, Peter Sandner, et al.
BJU International|September 8, 2006
Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptomsHanna Tinel, Beatrix Stelte-Ludwig, Joachim Hütter, et al.
Handbook of Experimental Pharmacology|December 1, 2016
Novel sGC Stimulators and sGC Activators for the Treatment of Heart FailureStefanie Breitenstein, Lothar Roessig, Peter Sandner, et al.
Hypertension (Dallas, Tex. : 1979)|January 19, 2002
Inflammatory cytokines stimulate adrenomedullin expression through nitric oxide-dependent and -independent pathwaysKarl-Heinz Hofbauer, Ellen Schoof, Armin Kurtz, et al.
Pageof 11